ArticleSpringerPlus2014

Zoledronic acid prevents decreases in bone mineral density in patients with prostate cancer undergoing combined androgen blockade.

Satoshi Nishizawa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.